X0508 4 2024-01-16 true 0001822462 Foghorn Therapeutics Inc. FHTX 0001714023 Reine Allan 500 TECHNOLOGY SQUARE STE #700 CAMBRIDGE MA 02139 false true false false Chief Financial Officer false Common Stock 53784.00 D Stock Options (Right to buy) 3.72 2029-09-16 Common Stock 257513.00 257513.00 D Stock Option (right to buy) 8.77 2030-08-17 Common Stock 91891.00 91891.00 D Stock Option (right to buy) 16.63 2031-01-27 Common Stock 120000.00 120000.00 D Stock Option (right to buy) 14.87 2032-01-25 Common Stock 135000.00 135000.00 D Stock Option (right to buy) 8.38 2033-01-25 Common Stock 90000.00 90000.00 D The option vested as to 25% of the underlying shares of common stock on September 17, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Exit Form 4 filed solely to report the Reporting Person is no longer an officer of the Issuer within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934, as amended. /s /Adrian Gottschalk, Attorney-in-Fact for Allan Reine 2024-01-17